Literature DB >> 10655067

Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation.

K Matsuo1, J M Owens, M Tonko, C Elliott, T J Chambers, E F Wagner.   

Abstract

Osteoclasts are bone-resorbing cells derived from haematopoietic precursors of the monocyte-macrophage lineage. Mice lacking Fos (encoding c-Fos) develop osteopetrosis due to an early differentiation block in the osteoclast lineage. c-Fos is a component of the dimeric transcription factor activator protein-1 (Ap-1), which is composed mainly of Fos (c-Fos, FosB, Fra-1 and Fra-2) and Jun proteins (c-Jun, JunB and JunD). Unlike Fra-1 (encoded by Fosl1), c-Fos contains transactivation domains required for oncogenesis and cellular transformation. The mechanism by which c-Fos exerts its specific function in osteoclast differentiation is not understood. Here we show by retroviral-gene transfer that all four Fos proteins, but not the Jun proteins, rescue the differentiation block in vitro. Structure-function analysis demonstrated that the major carboxy-terminal transactivation domains of c-Fos and FosB are dispensable and that Fra-1 (which lacks transactivation domains) has the highest rescue activity. Moreover, a transgene expressing Fra-1 rescues the osteopetrosis of c-Fos-mutant mice in vivo. The osteoclast differentiation factor Rankl (also known as TRANCE, ODF and OPGL; refs 8-11) induces transcription of Fosl1 in a c-Fos-dependent manner, thereby establishing a link between Rank signalling and the expression of Ap-1 proteins in osteoclast differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10655067     DOI: 10.1038/72855

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  97 in total

1.  RANKing c-Jun in osteoclast development.

Authors:  Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

2.  Maf promotes osteoblast differentiation in mice by mediating the age-related switch in mesenchymal cell differentiation.

Authors:  Keizo Nishikawa; Tomoki Nakashima; Shu Takeda; Masashi Isogai; Michito Hamada; Ayako Kimura; Tatsuhiko Kodama; Akira Yamaguchi; Michael J Owen; Satoru Takahashi; Hiroshi Takayanagi
Journal:  J Clin Invest       Date:  2010-09-27       Impact factor: 14.808

3.  Specificity of RGS10A as a key component in the RANKL signaling mechanism for osteoclast differentiation.

Authors:  Shuying Yang; Wei Chen; Philip Stashenko; Yi-Ping Li
Journal:  J Cell Sci       Date:  2007-10-01       Impact factor: 5.285

4.  A marine fungus-derived nitrobenzoyl sesquiterpenoid suppresses receptor activator of NF-κB ligand-induced osteoclastogenesis and inflammatory bone destruction.

Authors:  Yanhui Tan; Wende Deng; Yueyang Zhang; Minhong Ke; Binhua Zou; Xiaowei Luo; Jianbin Su; Yiyuan Wang; Jialan Xu; Kutty Selva Nandakumar; Yonghong Liu; Xuefeng Zhou; Xiaojuan Li
Journal:  Br J Pharmacol       Date:  2020-08-11       Impact factor: 8.739

5.  Transactivation of Fra-1 and consequent activation of AP-1 occur extracellular signal-regulated kinase dependently.

Authors:  Matthew R Young; Rajalakshmi Nair; Natalie Bucheimer; Preety Tulsian; Nicole Brown; Cristi Chapp; Tin-Chen Hsu; Nancy H Colburn
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

6.  c-Fos-deficient mice are susceptible to Salmonella enterica serovar Typhimurium infection.

Authors:  Kenta Maruyama; Gen-Ichiro Sano; Neelanjan Ray; Yasunari Takada; Koichi Matsuo
Journal:  Infect Immun       Date:  2006-12-18       Impact factor: 3.441

7.  Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis.

Authors:  Masashi Miyazaki; Yosuke Fujikawa; Chikahiro Takita; Hiroshi Tsumura
Journal:  Clin Rheumatol       Date:  2006-04-04       Impact factor: 2.980

Review 8.  Nuclear receptors in bone physiology and diseases.

Authors:  Yuuki Imai; Min-Young Youn; Kazuki Inoue; Ichiro Takada; Alexander Kouzmenko; Shigeaki Kato
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

9.  1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression.

Authors:  Sadaoki Sakai; Hironari Takaishi; Kenichiro Matsuzaki; Hironori Kaneko; Mitsuru Furukawa; Yoshiteru Miyauchi; Ayako Shiraishi; Keiji Saito; Akio Tanaka; Tadatsugu Taniguchi; Toshio Suda; Takeshi Miyamoto; Yoshiaki Toyama
Journal:  J Bone Miner Metab       Date:  2009-05-19       Impact factor: 2.626

Review 10.  Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Authors:  J L Sottnik; E T Keller
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.